BioSpace News Archive

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year ended December 31, 2018.

Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, presented in vivo proof of concept data for the DDS-04 series of new mechanism antibiotics targeting Enterobacteriaceae in an oral session at the 29th European Congress of Clinical Microbiology & Infectious Diseases (‘ECCMID’) in Amsterdam.

Calls out Suspicious Timing, Lack of Disclosure and Leadership as Confirmed by Negative Market Reaction

With respect to accuracy, interim clinical data demonstrated both positive and negative predictive value average of 84 percent.

• The Australian launch of VivaGel® BV (Fleurstat BVgel) is the first launch globally with further launches to follow in Europe and other regions • Fleurstat BVgel (VivaGel® BV) is marketed in Australia by Aspen • VivaGel® BV is an Australian innovation – a non-antibiotic therapy – which addresses a global unmet medical need

Bernstein Liebhard LLP announced that only 6 weeks remain to make a motion for lead plaintiff in a securities class action lawsuit alleging claims on behalf of those who purchased the securities of American Renal Associates Holdings, Inc. between August 10, 2016 and March 27, 2019, both dates inclusive.

RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased Care.com, Inc. between March 27, 2015 and April 1, 2019, inclusive.

CPhI data predicts India to be one of the world’s ‘fastest growing bio’ hubs in 2019, fuelled by new biosimilars production

Hagens Berman Sobol Shapiro LLP alerts investors in Zogenix, Inc. to the securities class action pending in the United States District Court for the Northern District of California and to the June 11, 2019 Lead Plaintiff deadline.

Integral Molecular announced the expansion of its two proprietary antibody characterization platforms, Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array.